RT Journal Article
T1 Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer
A1 Castillo Romero, Rafael
A1 Colilla Nieto, Montserrat
A1 Vallet Regí, María Dulce Nombre
AB Introduction: Nanocarriers have emerged as a powerful alternative for cancer therapy.Indeed, they are promising candidates to tackle the acquired resistance of surviving cells against antiproliferative drugs – the so-called multidrug resistance (MDR) phenomenon – which has arisen as one of the major clinical issues of chemotherapy. Among nanocarriers, this review focuses on the recent approaches based on tailored mesoporous silica  nanoparticles (MSNs) that could overcome this problem. Areas covered: Herein we summarize the current efforts developed to provide MSNbased nanosystems of enhanced dual therapeutic action against diseased cells. This can be accomplished by three main approaches: i) increasing nanosystems’ killing capability towards particular cells by enhancing both recognition and specificity; ii)increasing the apoptotic effect throughout co-delivery of several drugs; or iii)combining drug delivery with apoptosis induced by physical methods.Expert Opinion: The development of multifunctional nanosystems able to exert the optimal therapeutic action through the minimal administration constitutes a major challenge in nanomedicine. Recent developments in advanced MSN-based platforms for drug delivery represent promising avenues in the management of MDR associated with cancer therapy. All strategies discussed in this manuscript demonstrate improvements against difficult-to-treat tumors.
PB Taylor & Francis
SN 1742-5247
YR 2016
FD 2016-07-25
LK https://hdl.handle.net/20.500.14352/17581
UL https://hdl.handle.net/20.500.14352/17581
LA spa
NO RESEARCHER ID M-3378-2014 (María Vallet Regí)ORCID 0000-0002-6104-4889 (María Vallet Regí)
NO Unión Europea. H2020
NO Ministerio de Economía y Competitividad (MINECO)
NO Agening Network of Excellence
DS Docta Complutense
RD 8 abr 2025